Context Therapeutics Inc. (CNTX) stock
CNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.17−0.00 (-2.69%)
Close on Nov 18, 2026Market cap $15.29MP/E –Yield –
Context Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Context Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$34.03M. For fiscal 2025 it was -$26.42M. The highest annual figure on record is -$8.80M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$26.42M | – |
| FY2024 | Dec 31, 2024 | -$14.56M | – |
| FY2023 | Dec 31, 2023 | -$21.05M | – |
| FY2022 | Dec 31, 2022 | -$13.59M | – |
| FY2021 | Dec 31, 2021 | -$8.80M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.04M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.47M | – |
| Q4 FY2025 | Dec 31, 2025 | -$8.94M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.84M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.06M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.91M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.94M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.23M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.46M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.63M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.73M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.93M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.81M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.86M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.96M | – |
| Q3 FY2021 | Sep 30, 2021 | -$43.63K | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.08M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.72M | – |
See a number that looks wrong?